Can This Stock Grow Despite a COVID Testing Decline?

With U.S. COVID-19 cases expected to fall over 90% in the next six months, some investors may have concerns about genetic testing company Fulgent Genetics (NASDAQ: FLGT) -- one of the primary COVID-19 testing companies during the pandemic -- thinking that its success is over. This, however, is far from the case. 

Fulgent's core business has been growing by triple digits over the past several quarters, and its growth runway is extremely long. Fulgent could potentially be a successful investment over the next five years, despite its COVID-19 revenue slowdown. 

Image source: Getty Images.

Continue reading

Source Fool.com